HILBARI
Live / Allowed — Published for opposition (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 03 Oct 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99426804
- Mark type
- Stylized text
- Filed
- 03 Oct 2025
- Published for opposition
- 10 Mar 2026
- Attorney of record
- Matthew P. Hintz
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of mast-cell mediated disorders; Pharmaceutical preparations for the treatment of urticaria; Pharmaceutical preparations for the treatment of chronic spontaneous urticaria (CSU); Pharmaceutical preparations for the treatment of chronic inducible urticaria (CIndU); Pharmaceutical preparations for the treatment of prurigo nodularis (PN); Pharmaceutical preparations for the treatment of atopic dermatitis (AD); Pharmaceutical preparations for the treatment of cold urticaria (ColdU); Pharmaceutical preparations for the treatment of symptomatic dermographism (SD); Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of inflammatory diseases
Owner
- Celldex Therapeutics, Inc., Hampton, NJ, US
- Celldex Therapeutics, Inc., Hampton, NJ, US
Prosecution history
- 10 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 10 Mar 2026 — PUBLISHED FOR OPPOSITION
- 04 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 06 Feb 2026 — ASSIGNED TO EXAMINER
- 03 Oct 2025 — APPLICATION FILING RECEIPT MAILED
- 03 Oct 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 03 Oct 2025 — NEW APPLICATION ENTERED